AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11817713 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining habitual physical activity
Number of subjects: 30
Study 9742478 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric powder formulation of didanosine (ddI)
Number of subjects: 20
Study 9742478 — intervention group
Group type: COMPARATOR
Intervention: Buffered didanosine (ddI) tablets
Number of subjects: 20
Study 8061335 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (bismuth subcitrate 120 mgx4 + amoxycillin 500 mgx4 + metronidazole 250 mgx4)
Number of subjects: 46
Study 8061335 — intervention group
Group type: COMPARATOR
Intervention: Double therapy (amoxycillin 500 mgx4 + metronidazole 250 mgx4)
Number of subjects: 46
Study 8061335 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 46
Study 8061335 — intervention group
Group type: COMPARATOR
Intervention: Double therapy
Number of subjects: 46
Study 2564267 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized thiazinamium chloride (TC) 300 micrograms
Number of subjects: 15
Study 2564267 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized thiazinamium chloride (TC) 600 micrograms
Number of subjects: 15
Study 2564267 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized thiazinamium chloride (TC) 900 micrograms
Number of subjects: 15
Study 2564267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2564267 — intervention group
Group type: EXPERIMENTAL
Intervention: Active control drug (metaproterenol or cromolyn)
Number of subjects: 15
Study 4121478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (1.25 mg)
Number of subjects: 0
Study 4121478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.95 mg)
Number of subjects: 0
Study 4121478 — intervention group
Group type: COMPARATOR
Intervention: Morphine (10 mg)
Number of subjects: 0
Study 31373222 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART Camp intervention
Number of subjects: 204
Study 31373222 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 204
Study 30941931 — intervention group
Group type: EXPERIMENTAL
Intervention: cTTE (contrast transthoracic echocardiography)
Number of subjects: 0
Study 30941931 — intervention group
Group type: COMPARATOR
Intervention: cTCD (contrast transcranial Doppler)
Number of subjects: 0
Study 30941931 — intervention group
Group type: COMPARATOR
Intervention: cTCD
Number of subjects: 0
Study 28332420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (informed of 6-month follow-up at fitting)
Number of subjects: 181
Study 28332420 — intervention group
Group type: COMPARATOR
Intervention: Control group (informed just prior to follow-up)
Number of subjects: 181
Study 28332420 — intervention group
Group type: EXPERIMENTAL
Intervention: Datalogging (objective assessment)
Number of subjects: 181
Study 28332420 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report (subjective assessment)
Number of subjects: 181
Study 28332420 — intervention group
Group type: EXPERIMENTAL
Intervention: More severe hearing impairment and prior hearing aid experience
Number of subjects: 181
Study 26135276 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based prevention manual
Number of subjects: 0
Study 26135276 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic public health intervention
Number of subjects: 0
Study 23275081 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilised (PS) TKA
Number of subjects: 40
Study 23275081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate-retaining (CR) TKA
Number of subjects: 40
Study 21480732 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (7 mg/24 h)
Number of subjects: 29
Study 21480732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 18639300 — intervention group
Group type: EXPERIMENTAL
Intervention: Double layer urethrovesical anastomosis
Number of subjects: 116
Study 18639300 — intervention group
Group type: COMPARATOR
Intervention: Single layer urethrovesical anastomosis
Number of subjects: 116
Study 17354095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling + subgingival irrigation with 0.5% PVP-iodine for 5 min/tooth
Number of subjects: 20
Study 17354095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling + subgingival irrigation with sterile saline solution for 5 min/tooth
Number of subjects: 20
Study 17354095 — intervention group
Group type: COMPARATOR
Intervention: Subgingival irrigation with sterile saline solution for 5 min/tooth
Number of subjects: 20
Study 17354095 — intervention group
Group type: COMPARATOR
Intervention: Subgingival irrigation with 0.5% PVP-iodine for 5 min/tooth
Number of subjects: 20
Study 14977032 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who committed a mock theft of a dollar and were asked questions about an outside issue
Number of subjects: 192
Study 14977032 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who committed a mock theft of a dollar and were not asked questions about an outside issue
Number of subjects: 192
Study 14977032 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who did not commit a mock theft and were asked questions about an outside issue
Number of subjects: 192
Study 14977032 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who did not commit a mock theft and were not asked questions about an outside issue
Number of subjects: 192
Study 11291467 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9512672 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by radiotherapy
Number of subjects: 0
Study 9512672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and vinblastine followed by radiotherapy and concomitant carboplatin
Number of subjects: 0
Study 9512672 — intervention group
Group type: COMPARATOR
Intervention: Standard regional therapy with radiotherapy and surgery
Number of subjects: 0
Study 9512672 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy, surgery, and radiotherapy (previously piloted approach)
Number of subjects: 0
Study 9512672 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, gemcitabine, and vinorelbine in combination with cisplatin
Number of subjects: 0
Study 7844211 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 beta‐methylprednisolone (0, 16 or 60 mg/day) for 4 days from the day of oocyte retrieval
Number of subjects: 0
Study 7844211 — intervention group
Group type: COMPARATOR
Intervention: Control group (no corticosteroid treatment)
Number of subjects: 0
Study 3348163 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride supplementation (10 or 20 mg F/d as sodium fluoride) during bed rest weeks 6-10
Number of subjects: 15
Study 3348163 — intervention group
Group type: COMPARATOR
Intervention: Bed rest (weeks 6-10)
Number of subjects: 15
Study 30558466 — intervention group
Group type: EXPERIMENTAL
Intervention: myo‐inositol
Number of subjects: 0
Study 30558466 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐chiro‐inositol
Number of subjects: 0
Study 30558466 — intervention group
Group type: EXPERIMENTAL
Intervention: myo‐inositol/D‐chiro‐inositol
Number of subjects: 0
Study 30558466 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 31037967 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib maintenance therapy after first-line chemotherapy
Number of subjects: 0
Study 31037967 — intervention group
Group type: COMPARATOR
Intervention: Placebo maintenance therapy after first-line chemotherapy
Number of subjects: 0
Study 30020266 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive bone conduction hearing system
Number of subjects: 17
Study 30020266 — intervention group
Group type: COMPARATOR
Intervention: CROS hearing aid
Number of subjects: 17
Study 26518420 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month dual antiplatelet therapy (DAPT) after CoCr-EES implantation
Number of subjects: 1525
Study 26518420 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month DAPT after CoCr-EES implantation
Number of subjects: 1525
Study 25524969 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein plus potassium bicarbonate supplement
Number of subjects: 10
Study 25524969 — intervention group
Group type: COMPARATOR
Intervention: No supplement (control)
Number of subjects: 10
Study 22215056 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical alert directed to the provider suggesting adding a problem to the electronic problem list based on inference rules.
Number of subjects: 28
Study 22215056 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clinical alert).
Number of subjects: 28
Study 19091800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (1.5 g/d (n‐3) LCPUFA)
Number of subjects: 122
Study 19091800 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO) supplementation
Number of subjects: 122
Study 19091800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 122
Study 17628346 — intervention group
Group type: EXPERIMENTAL
Intervention: Project EX-4 intervention (8 session classroom-based curriculum)
Number of subjects: 1097
Study 17628346 — intervention group
Group type: COMPARATOR
Intervention: Control condition (standard care)
Number of subjects: 1097
Study 16225529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical sodium hyaluronate (6 weekly doses)
Number of subjects: 38
Study 12192465 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term training of GPs (half a day)
Number of subjects: 16
Study 12192465 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 GPs, no training)
Number of subjects: 16
Study 9789914 — intervention group
Group type: EXPERIMENTAL
Intervention: Population based smoothing methods derived from a random‐effects model plus a stochastic process or individual based smoothing methods
Number of subjects: 0
Study 9789914 — intervention group
Group type: EXPERIMENTAL
Intervention: Imputes in a time‐dependent Cox model
Number of subjects: 0
Study 8131242 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (275 mg x 2 capsules, total 550 mg)
Number of subjects: 66
Study 8131242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 2680272 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce calorie intake
Number of subjects: 841
Study 2680272 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium intake
Number of subjects: 841
Study 2680272 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and calorie intake
Number of subjects: 841
Study 2680272 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and increase potassium intake
Number of subjects: 841
Study 2680272 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 841
Study 30343590 — intervention group
Group type: EXPERIMENTAL
Intervention: IA-PRP injections (2 ultrasound-guided injections)
Number of subjects: 33
Study 30343590 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (2 ultrasound-guided intra-articular methylprednisolone and lidocaine injections at a 2-week interval)
Number of subjects: 33
Study 31192569 — intervention group
Group type: EXPERIMENTAL
Intervention: Total activity energy expenditure
Number of subjects: 2888
Study 31192569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of vigorous-intensity physical activity (PA)
Number of subjects: 2888
Study 31192569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of moderate activity energy expenditure
Number of subjects: 2888
Study 31192569 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-leisure-time physical activity (PA)
Number of subjects: 2888
Study 31192569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 2888
Study 31192569 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable intake
Number of subjects: 2888
Study 28239919 — intervention group
Group type: EXPERIMENTAL
Intervention: MiQuit (text message intervention)
Number of subjects: 407
Study 28239919 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 407
Study 25157964 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT plus clozapine
Number of subjects: 39
Study 25157964 — intervention group
Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 39
Study 25157964 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover phase (ECT after clozapine nonresponse)
Number of subjects: 39
Study 23219613 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) of the ankle joint for 1 hour a day, 5 days a week for 4 weeks
Number of subjects: 14
Study 23219613 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) of the ankle joint
Number of subjects: 14
Study 22018126 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg ethinyl estradiol and 3 mg drospirenone 21/7 regimen (Group 1) for 6 months
Number of subjects: 50
Study 22018126 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg ethinyl estradiol and 3 mg drospirenone 24/4 regimen (Group 2) for 6 months
Number of subjects: 50
Study 22018126 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 18649072 — intervention group
Group type: EXPERIMENTAL
Intervention: DMT
Number of subjects: 14
Study 18649072 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 14
Study 18649072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16574042 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization
Number of subjects: 103
Study 16574042 — intervention group
Group type: COMPARATOR
Intervention: Immobilization
Number of subjects: 103
Study 12783230 — intervention group
Group type: COMPARATOR
Intervention: Backpack of 0% body mass
Number of subjects: 15
Study 12783230 — intervention group
Group type: COMPARATOR
Intervention: Backpack of 10% body mass
Number of subjects: 15
Study 12783230 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack of 15% body mass
Number of subjects: 15
Study 12783230 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack of 20% body mass
Number of subjects: 15
Study 10714852 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol and alfentanil
Number of subjects: 20
Study 10714852 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar local block
Number of subjects: 20
Study 8956797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 40 mg m-2 + Etoposide (VP16) 100 mg m-2 on days 1-3 (arm A)
Number of subjects: 112
Study 8956797 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP) 30 mg m-2 on days 2 and 3 + Carboplatin (CBDCA) 250 mg m-2 on day 1 + Etoposide (VP16) 100 mg m-2 on days 1-3 + Vinorelbine (NVB) 30 mg m-2 on day 1 (arm B)
Number of subjects: 112
Study 8956797 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental regimen (arm B)
Number of subjects: 112
Study 8956797 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (arm A)
Number of subjects: 112
Study 8956797 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (arm A)
Number of subjects: 112
Study 8956797 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 112
Study 1525748 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fluid intake (50% more than normal)
Number of subjects: 10
Study 1525748 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased fluid intake (50% less than normal)
Number of subjects: 10
Study 2410317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (24 +/- 13 g/day)
Number of subjects: 10
Study 2410317 — intervention group
Group type: COMPARATOR
Intervention: Sodium cyclamate (348 +/- 270 mg/day)
Number of subjects: 10
Study 2410317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 10
Study 2410317 — intervention group
Group type: COMPARATOR
Intervention: Sodium cyclamate
Number of subjects: 10
Study 29301920 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin for 18 months
Number of subjects: 371
Study 29301920 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 18 months
Number of subjects: 371
Study 27922214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tier One Word Generation (WG) program
Number of subjects: 0
Study 27922214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tier Two Strategic Adolescent Reading Intervention (STARI)
Number of subjects: 0
Study 24309085 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandparent Triple P intervention
Number of subjects: 54
Study 24309085 — intervention group
Group type: COMPARATOR
Intervention: Control group (grandparent care-as-usual)
Number of subjects: 54
Study 22472463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Rehabilitation Program (PFRP)
Number of subjects: 34
Study 22472463 — intervention group
Group type: COMPARATOR
Intervention: Usual health care (non-PFRP)
Number of subjects: 34
Study 20688862 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume targeted ventilation at 4 ml/kg
Number of subjects: 18
Study 20688862 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume targeted ventilation at 6 ml/kg
Number of subjects: 18
Study 20688862 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no volume targeting)
Number of subjects: 18
Study 18466045 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 24
Study 18466045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15845715 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating catheter technique
Number of subjects: 81
Study 15845715 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (blind advancement)
Number of subjects: 81
Study 15845715 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 81
Study 14619648 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH (rFSH)
Number of subjects: 131
Study 11056973 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stenting
Number of subjects: 23
Study 11056973 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 23
Study 11056973 — intervention group
Group type: COMPARATOR
Intervention: Follow-up examinations (neurological assessment including duplex sonography)
Number of subjects: 23
Study 8985717 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 8
Study 8985717 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 8
Study 8985717 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 8985717 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH challenge
Number of subjects: 8
Study 1420528 — intervention group
Group type: EXPERIMENTAL
Intervention: Braden Scale for Predicting Pressure Sore Risk
Number of subjects: 0
Study 1420528 — intervention group
Group type: COMPARATOR
Intervention: Nurse judgment prediction method
Number of subjects: 0
Study 1420528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention measures
Number of subjects: 0
Study 6380331 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol administration of 400 micrograms beclomethasone dipropionate
Number of subjects: 40
Study 6380331 — intervention group
Group type: COMPARATOR
Intervention: Powder administration of 400 micrograms beclomethasone dipropionate (Rotacaps)
Number of subjects: 40
Study 31190751 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg midazolam
Number of subjects: 120
Study 31190751 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg midazolam
Number of subjects: 120
Study 31190751 — intervention group
Group type: COMPARATOR
Intervention: Control with saline
Number of subjects: 120
Study 28687982 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB plus PCI (group B, ACB with 0.375% ropivacaine 30 ml + PCI with 0.2% ropivacaine 50 ml)
Number of subjects: 60
Study 28687982 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB plus PCI (group B)
Number of subjects: 60
Study 28687982 — intervention group
Group type: COMPARATOR
Intervention: ACB (group A, ACB with 0.375% ropivacaine 30 ml)
Number of subjects: 60
Study 28687982 — intervention group
Group type: COMPARATOR
Intervention: LIA (group C, local infiltration with 0.2% ropivacaine 100 ml)
Number of subjects: 60
Study 27938853 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet at low sodium
Number of subjects: 103
Study 27938853 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet at medium sodium
Number of subjects: 103
Study 27938853 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet at high sodium
Number of subjects: 103
Study 27938853 — intervention group
Group type: COMPARATOR
Intervention: Control diet (average American diet) at low sodium
Number of subjects: 103
Study 27938853 — intervention group
Group type: COMPARATOR
Intervention: Control diet (average American diet) at medium sodium
Number of subjects: 103
Study 27938853 — intervention group
Group type: COMPARATOR
Intervention: Control diet (average American diet) at high sodium
Number of subjects: 103
Study 25295648 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 116
Study 25295648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 22897915 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI and bevacizumab for 3 months pre- and postoperative and resection (PERIMAX)
Number of subjects: 380
Study 22897915 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with FOLFOX and bevacizumab +/- irinotecan for a maximum of 6 months followed by maintenance treatment with fluoropyrimidine and bevacizumab (CHARTA)
Number of subjects: 380
Study 22897915 — intervention group
Group type: COMPARATOR
Intervention: Postoperative FOLFOX for 6 months (PERIMAX)
Number of subjects: 380
Study 22897915 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX and bevacizumab +/- irinotecan for a maximum of 6 months (CHARTA)
Number of subjects: 380
Study 19383058 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg
Number of subjects: 11
Study 19383058 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metoprolol 190 mg
Number of subjects: 11
Study 19383058 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose metoprolol 95 mg
Number of subjects: 11